昂丹司琼,临床注释-2,变异和临床注释数据

昂丹司琼

临床注释ID

982014094

药物名称(英)

ondansetron

变异单倍型

CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN

基因

CYP2D6

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Efficacy

表现型类别

功效

分数

102.25

PMID计数

计数的证据

表现型

呕吐

表现型(英)

Vomiting

最新日期

2021/9/16 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/982014094

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1063	*35xN	The CYP2D635xN alleles (35x2) is assigned as an increased function allele by CPIC. Patients carrying a 35xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a 35xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *35xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1062	*10	The CYP2C610 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the 10 allele in combination with a decreased or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1061	*5	The CYP2D65 allele has been assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1060	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1059	*2xN	The CYP2D62xN alleles (2x2 and 2x鈮?) are assigned as increased function alleles by CPIC. Patients carrying a 2xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a 2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a 2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1058	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients carrying the 2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1057	*1xN	The CYP2D61xN alleles (1x2 and 1x鈮?) are assigned as increased function alleles by CPIC. Patients carrying a 1xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a 1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a 1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.
1056	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.

临床证据

id	证据的ID	总结
3939	981954745	CYP2D6 2/2 + 2/10 are not associated with response to ondansetron in people with Neoplasms.
3938	982006805	CYP2D6 1xN + 2xN are not associated with response to ondansetron in women as compared to CYP2D6 *5.
3937	982006758	CYP2D6 1xN + 2xN are associated with decreased response to ondansetron in women as compared to CYP2D6 *1.
3936	981954714	CYP2D6 1/1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.
3935	PA166161954	Annotation of CPIC Guideline for ondansetron and CYP2D6

临床病史

id	类型	评论
837	Update	Consolidated multiple VAs from same publication
836	Update	CA score added as part of scoring system release. LOE assigned following curator review.
835	Update	Edited phenotype descriptions and added limited evidence tag to *35xN
834	Update	Rewrote phenotype descriptions and added CPIC guideline
833	Update	Allele descriptions. This diverges from the standard sentence given that comparison is UM vs other phenotypes not necessarily only *1
832	Update	modified to allele description
831	Update	Updated 'extensive metabolizer' term to 'normal metabolizer' following CPIC Term Standardization Project.
830	Update
829	Update	Added 2 studies. Neither saw an association with CYP2D6 metabolizer status and ondansetron concentration.

最新招商产品更多>>